Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Docosapentaenoic acid (DPA) is an omega-3 fatty acid found in fish oil and certain marine sources, structurally related to EPA and DHA. Its use for the support or treatment of Metabolic Syndrome is based on emerging scientific evidence, though the body of research is significantly smaller than for EPA or DHA. Metabolic Syndrome is a cluster of conditions—including insulin resistance, hypertension, dyslipidemia, and central obesity—that increase cardiovascular risk. Omega-3 fatty acids have long been studied for their benefits in cardiovascular health and metabolic pathways. Some preclinical studies and a small number of human trials suggest that DPA may exert beneficial effects on lipid profiles, inflammation, and endothelial function, all of which are relevant to Metabolic Syndrome. For example, DPA has been shown in vitro and in animal models to reduce triglycerides, suppress inflammatory cytokines, and improve insulin sensitivity. Limited epidemiological studies also indicate an inverse association between DPA levels and the prevalence of metabolic syndrome or its components. However, direct clinical trials specifically investigating DPA supplementation in people with Metabolic Syndrome are sparse. Most human data come from studies where DPA is present alongside EPA and DHA, making it difficult to isolate its specific effects. Therefore, while there is promising mechanistic and early clinical evidence, the overall scientific validation remains preliminary, justifying a moderate-low evidence score.

More about DPA (docosapentaenoic acid)
More about Metabolic Syndrome

Other ingredients used for Metabolic Syndrome

Other health conditions supported by DPA (docosapentaenoic acid)

Products containing DPA (docosapentaenoic acid)

Pure Encapsulations Pro-Resolve Omega
Douglas Laboratories QÜELL® FISH OIL DHA Ultra SPM